FY25 consensus $11.98. Guidance includes an unfavorable impact of 55c per share related to acquired IPR&D and milestones expense incurred year-to-date through the second quarter 2025. The company’s 2025 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond the second quarter of 2025, as both cannot be reliably forecasted.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie reports Q2 adjusted EPS $2.97, consensus $2.91
- Options Volatility and Implied Earnings Moves Today, July 31, 2025
- M&A News: AbbVie Eyes $1B Acquisition of Gilgamesh Therapeutics
- Is ABBV Stock (ABBV) a Buy Ahead of Q2 Earnings?
- AbbVie in discussions to buy Gilgamesh in $1B deal, Bloomberg reports